Skip to main content
Signal8

Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc.

NASDAQ:DWTXHealthcare
+3.81%$1.10
Mkt Cap$42.07M
EV-
Float9.46M
O/S38.23M
VOL81K sh
$ Vol$92K
RVOL0.77×
Inst Own10.5%
SI1.2%
Net Cash/Sh-
Dilution
Dogwood Therapeutics, Inc. logoNASDAQ:DWTX$1.10+3.81%
Pipeline1 lead-sponsored trial·1 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Phase 2
    Active, not recruiting

    Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

    Halneuron, Placebo

    Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy +1

    Enrollment
    240
    Start
    Feb 2025
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT06848348